# Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer

> **NCT00227721** · PHASE2 · COMPLETED · sponsor: **Robert Morris** · enrollment: 30 (actual)

## Conditions studied

- Ovarian Cancer
- Peritoneal Cavity Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00227721
- **Lead sponsor:** Robert Morris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2011-06
- **Final completion:** 2017-02
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00227721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00227721, "Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00227721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*